Anlon Healthcare Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 9,975,000 (75%) | — | ₹9,077 Cr |
| NII (HNI) | — | 1,995,000 (15%) | — | ₹1,815 Cr |
| Retail | — | 1,330,000 (10%) | — | ₹1,210 Cr |
| Σ Total | — | 13,300,000 (100%) | — | ₹121,030 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 164 | ₹14,924 |
| Retail (Max) | 13 | 2,132 | ₹194,012 |
| S-HNI (Min) | 14 | 2,296 | ₹208,936 |
| B-HNI (Min) | 67 | 10,988 | ₹999,908 |
Financial Statements Amount in Crore
| Metric | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Revenue | 120 | 67 | 113 |
| EBITDA | 32 | 16 | 13 |
| Profit After Tax | 21 | 10 | 6 |
| Net Worth | 80 | 21 | 7 |
| Total Assets | 181 | 128 | 112 |
| Reserves & Surplus | 41 | 5 | -5 |
| Total Borrowing | 58 | 75 | 66 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- 1 Funding capital expenditure requirements for Proposed Expansion – 30.72
- 2 Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company – 5.00
- 3 Funding the working capital requirements of the Company – 43.15
- 4 General corporate purposes – 270.30
Company Overview
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs).
The company manufactures high-purity pharmaceutical intermediates (for API production) and active pharmaceutical ingredients (used in formulations for medicines, nutraceuticals, personal care, and animal health products).
The company offers pharmaceutical intermediates, APIs for medicines, nutraceuticals, personal care, and veterinary products, all manufactured following Indian and international pharmacopeia standards like IP, BP, EP, JP, and USP.
In addition to manufacturing Pharma Intermediates and APIs to global standards, the company now offers custom manufacturing for complex chemicals, exceeding purity standards and reducing impurities to meet specific customer needs.
The company has received Drug Master File (DMF) approval from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. The company has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals.
The company ensures product quality through rigorous testing, analysis, and process improvements. Supported by four labs, the 34-member team, including 24 science graduates, ensures products meet customer and industry standards.
The company's product portfolio consists of sixty-five (65) commercialised products and twenty-eight (28) products at pilot stage and forty-nine (49) products at laboratory testing stage/ laboratory scale stage.
Products:
- Pharma Intermediates:Cyanoethylbe nzoic acid, Ketonitrile and Methyldeslor atadine, these serve as a key starting material or as an advance intermediate for manufacturing of APIs.
- Active Pharmaceutical Ingredients: The company’s APIs are key components in pharmaceutical products, delivering therapeutic effects. They are used in formulations like tablets, capsules, ointments, syrups, and in nutraceuticals, personal care, and veterinary products.
Competitive Strengths:
- Strong product portfolio and scalable business.
- Strong Promoters and Experienced Management Team.
- High entry and exit barriers due to long customer approval cycles and strict product standards.
- In-house Testing, Quality Control and Quality Assurance for quality control.
- Focus on Quality, Environment, Health and Safety.